Roche Appeals FDA Decision on Avastin

Article

Genentech, owner of Roche, submitted its response yesterday to the FDA’s proposal to withdraw approval for Avastin (bevacizumab) for the treatment of HER2-negative metastatic breast cancer.

Image source: Roche

Last year, based on the results of four clinical studies of Avastin in women with HER-2 negative metastatic breast cancer, the FDA stated that it believes that the drug does not prolong overall survival in breast cancer patients or provide sufficient benefit in slowing disease progression to counterbalance the risk it poses from side effects.

Genentech has a legal right to a hearing to allow "full and fair discussion of the issues in a public forum.” At this hearing, the company will present data and analyses in an effort to demonstrate why Avastin should remain on the market.

Roche has had several setbacks in trying to extend the use of this very lucrative compound: Avastin earned the company nearly six billion last year in its currently-approved indications.Genentech believes that women afflicted with metastatic breast cancer should be allowed Avastin as an FDA-approved choice and that accelerated approval of the drug in combination with paclitaxel should be maintained. The European Medicines Agency has already confirmed that the benefits of Avastin in combination with paclitaxel outweigh the risks and considers this a viable treatment option in women with metastatic breast cancer.

Genentech has said that it will conduct a second trial of Avastin plus paclitaxel in patients with HER2-negative metastatic breast cancer. The trial, the original version of which was used as the basis for the agency's accelerated approval of Avastin, would include a biomarker component designed to identify people who are more likely to experience the greatest benefit from Avastin.
 

Related Videos
Administering immunotherapy following surgery in patients with early-stage triple-negative breast cancer does not appear to be as effective as beginning with neoadjuvant treatment, says Peter Schmid, MD, PhD.
Heather A. Parsons, MD, MPH, says she is excited about HER2 as a biomarker and investigating the biology of metastatic breast cancer with a minimally invasive liquid biopsy platform.
Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.
The Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.
The goal of creating the Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital is to establish a safe space for Hispanic patients, says Claudia Tellez, MD.
Several factors may contribute to the low Hispanic breast cancer population at Northwestern Memorial Hospital, including a lack of resources and a focus on other disease types.
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Related Content
Treatment with atezolizumab among patients with HER2-positive breast cancer in the phase 3 APTneo Michelangelo trial produces no major tolerability issues, says Luca Gianni, MD.

Atezolizumab Combo Numerically Improves pCR in HER2+ Operable Breast Cancer

December 9th 2023
Article

Treatment with atezolizumab among patients with HER2-positive breast cancer in the phase 3 APTneo Michelangelo trial produces no major tolerability issues, says Luca Gianni, MD.

Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.

Experts Discuss Differences in Radiotherapy Outcomes in BRCA+ Breast Cancer

October 30th 2023
Podcast

Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.

Latin American patients appear more likely to be diagnosed with aggressive early-stage breast cancer based on factors including metabolics and genetics, according to findings from the FLEX study.

Metabolism, Genetics May Impact Tumor Biology in Breast Cancer Populations

December 8th 2023
Article

Latin American patients appear more likely to be diagnosed with aggressive early-stage breast cancer based on factors including metabolics and genetics, according to findings from the FLEX study.

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023
Podcast

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Investigators observe no new safety signals with trastuzumab emtansine as a treatment for HER2-positive breast cancer after 8 years of follow-up in the phase 3 KATHERINE study.

T-DM1 Improves OS/iDFS Vs Trastuzumab in HER2+ Breast Cancer

December 8th 2023
Article

Investigators observe no new safety signals with trastuzumab emtansine as a treatment for HER2-positive breast cancer after 8 years of follow-up in the phase 3 KATHERINE study.

Future research may focus on the relationship between neoadjuvant chemotherapy regimens, pathologic complete response, and whole transcriptome changes in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.

Profiling Tests May Predict Chemo Efficacy in Early-Stage Breast Cancer

December 8th 2023
Article

Future research may focus on the relationship between neoadjuvant chemotherapy regimens, pathologic complete response, and whole transcriptome changes in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.